Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

  • Conferences
    • AACR20
    • AACR19
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR IO
    • AAI ASGCT
    • ASCO GI
    • ASCO GU
    • ASCO-SITC
    • ASCO20
    • ASCO19
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASH19
    • ASH18
    • ASH17
    • ASH16
    • ASH15
    • AUA
    • BMT
    • CIML40
    • CIMT
    • EACR
    • EAU
    • ECCO
    • EHA iCML
    • ESMO20
    • ESMO19
    • ESMO18
    • ESMO17
    • ESMO16
    • ESMO14
    • JPM20
    • SABCS
    • SITC 2019
    • SITC 2018
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
  • Targets
    • Adenosine
    • Bispecifics
    • Cytokines
    • MYC
    • Neoantigens
    • RAS
    • STING
  • About
  • Contact
  • Pricing
  • Cell Therapy
  • Immuno-Oncology
  • Targets Conf
  • Premium Content
  • Interviews
  • Login

  • What can we learn from Mirati’s adagrasib in lung and other cancers?

    Read more

  • TRIPLE highlights and lowlights in Developmental Therapeutics

    Read more

  • On finding new targets and boosting existing therapies

    Read more

  • Potential new targets and biomarkers for immunotherapy

    Read more

  • New developments in the KRAS landscape

    Read more

  • A contrarian view of key cancer trial results

    Read more
E

What can we learn from Mirati’s adagrasib in lung and other cancers?

It’s time to look at the latest update on KRAS mutation…

View post
E

TRIPLE highlights and lowlights in Developmental Therapeutics

The trials and tribulations of targeted agents in developmental therapeutics

View post
E

On finding new targets and boosting existing therapies

Science drives oncology new product development and the AACR special…

View post

Terms of Use & Privacy Policy
Copyright © 2010-20 Biotech Strategy Blog

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!